UK Chooses Pfizer And Moderna For COVID-19 Boosters, But Questions Remain On Unpublished Trial Data
AstraZeneca's Vaccine Not Selected
The UK’s choice of the mRNA vaccines as COVID-19 boosters is no surprise – but not releasing the key study data behind the decision is.
You may also be interested in...
As questions of political interference continue to swirl around the issue of whether additional vaccine shots will be needed, the Biden administration is facing communication challenges commonly seen with his predecessor, Donald Trump.
Results will be important in fight against new variants, for second-generation vaccines and AstraZeneca’s controversy-hit jab.
The VC firm is making the most of a surge of capital from new and established investors who believe in the promise of European biopharma start-ups.